Apyx Medical Corporation (NASDAQ:APYX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Apyx Medical Corporation (NASDAQ:APYX) has been assigned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $6.60.

A number of analysts recently weighed in on the company. HC Wainwright began coverage on Apyx Medical in a research note on Monday, July 13th. They issued a “buy” rating and a $7.00 price target on the stock. Wall Street Zen cut Apyx Medical from a “buy” rating to a “hold” rating in a research report on Sunday, April 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Apyx Medical in a report on Wednesday, June 24th. Finally, Zacks Research upgraded shares of Apyx Medical to a “hold” rating in a research report on Tuesday, July 14th.

Institutional Trading of Apyx Medical

A number of institutional investors have recently added to or reduced their stakes in the stock. Nantahala Capital Management LLC increased its holdings in Apyx Medical by 19.1% in the fourth quarter. Nantahala Capital Management LLC now owns 3,974,091 shares of the company’s stock valued at $13,909,000 after buying an additional 636,043 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Apyx Medical by 3.6% during the 3rd quarter. Vanguard Group Inc. now owns 1,528,947 shares of the company’s stock worth $3,272,000 after acquiring an additional 53,175 shares in the last quarter. AIGH Capital Management LLC purchased a new stake in shares of Apyx Medical during the 4th quarter worth approximately $3,867,000. Silverberg Bernstein Capital Management LLC boosted its stake in shares of Apyx Medical by 0.8% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 1,041,070 shares of the company’s stock worth $3,842,000 after acquiring an additional 8,067 shares in the last quarter. Finally, Sei Investments Co. grew its holdings in shares of Apyx Medical by 298.6% in the 1st quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock worth $2,208,000 after acquiring an additional 448,174 shares during the period. Hedge funds and other institutional investors own 55.33% of the company’s stock.

Apyx Medical Trading Down 1.4%

NASDAQ APYX opened at $4.28 on Tuesday. The stock has a market capitalization of $179.38 million, a P/E ratio of -19.45 and a beta of 1.37. Apyx Medical has a 52-week low of $1.59 and a 52-week high of $5.08. The firm has a 50-day moving average price of $4.24 and a 200 day moving average price of $3.90. The company has a quick ratio of 4.79, a current ratio of 5.80 and a debt-to-equity ratio of 2.68.

Apyx Medical (NASDAQ:APYX) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.06. Apyx Medical had a negative net margin of 16.40% and a negative return on equity of 88.47%. The firm had revenue of $12.49 million during the quarter, compared to the consensus estimate of $10.53 million. Equities research analysts expect that Apyx Medical will post -0.21 EPS for the current year.

Apyx Medical Company Profile

Apyx Medical (NASDAQ: APYX) is a medical device company focused on the development and commercialization of energy-based solutions for surgical and aesthetic applications. The company’s product portfolio includes devices that utilize radiofrequency energy, cold plasma and proprietary technologies designed to deliver precise thermal control and tissue treatment. Its key offerings encompass the J-Plasma technology under the Renuvion brand, which is primarily used for subdermal skin tightening and aesthetic procedures, and its portfolio of advanced energy medical devices for general surgery, gynecology and dermatology.

Leveraging its dual focus on surgical and aesthetic markets, Apyx Medical serves physicians and healthcare providers across North America, Europe and select international regions.